Ferenc Follath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ferenc Follath has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
A. Mclean
University of Sydney
1 shared publication- Alexandre Mebazaa
Intensive Care Department, Hôpital Lariboisière, Sorbone University , Paris
1 shared publication - Etienne Gayat
Department of Anesthesiology, Burn and Critical Care, University Hospitals Saint-Louis—Lariboisière, AP-HP, Paris, France
1 shared publication F. Vilas-Boas
Hospital Espanhol
1 shared publicationFatima Franco
Coimbra University Hospital, Coimbra, Portugal
1 shared publication- Fábio Vilas-Boas
Santa Casa de Misericórdia da Bahia
1 shared publication
Latest Publications
- 1 January 2015
- Published by Hogrefe Publishing Group in Praxis
- Vol. 104 (20) , 1105
Antworten zu den Fragen zu «Kardiovaskuläre Medikamente bei alten und multimorbiden Patienten» aus PRAXIS Nr. 19
- 1 January 2015
- Published by Hogrefe Publishing Group in Praxis
- Vol. 104 (20) , 1105
Antworten zu den Fragen zu «Kardiovaskuläre Medikamente bei alten und multimorbiden Patienten» aus PRAXIS Nr. 19
- 6 January 2011
- Published by Springer Nature in Intensive Care Medicine
- Vol. 37 (4) , 619-626
Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF)
We performed a survey on acute heart failure (AHF) in nine countries in four continents. We aimed to describe characteristics and management of AHF among various countries, to compare patients with de novo AHF versus patients with a pre-existing episode of AHF, and to describe subpopulations hospitalized in intensive care unit (ICU) versus cardiac care unit (CCU) versus ward.
- 6 January 2011
- Published by Springer Nature in Intensive Care Medicine
- Vol. 37 (4) , 619-626
Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF)
We performed a survey on acute heart failure (AHF) in nine countries in four continents. We aimed to describe characteristics and management of AHF among various countries, to compare patients with de novo AHF versus patients with a pre-existing episode of AHF, and to describe subpopulations hospitalized in intensive care unit (ICU) versus cardiac care unit (CCU) versus ward.
- 10 November 2009
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 23 (6) , 669-673
Ethical considerations in cardiovascular prevention
The fundamental values in medical ethics include the following aspects of professional conduct: (i) actions in the best interest of patients; (ii) first, do no harm; (iii) patients' right to refuse or choose treatments; (iv) fairness and equality in the distribution of healthcare resources; and (v) truthfulness and honesty (informed consent). These values have to be considered in all diagnostic steps and therapeutic decisions. They should also form the basis for discussions of potential conflicts of interest among patients, doctors, healthcare financers and politicians. Cardiovascular (CV) diseases represent the most frequent cause of death and a major healthcare problem in most regions of the world. CV prevention is therefore an important task both in individual subjects and as a means to improve health in the general population. While the merits of treatment in patients with established CV diseases, i.e. secondary prevention, are widely accepted and regarded as necessary, primary prevention with drugs in apparently healthy individuals at an increased risk of future CV events is not free of controversies. The different types of prevention envisaged also give rise to ethical questions: Should all the growing number of classical and newly recognised CV risk markers be a reason for intervention or should they be preferably used for calculating a total risk score? What are the compelling or only relative indications for anti-hypertensive, cholesterol-lowering, anti-diabetic or platelet-inhibiting drugs? Are pre-hypertension, pre-diabetes and marginally elevated cholesterol levels early diseases justifying drug treatment, regardless of the possibility that some prophylactic interventions may be associated with adverse events? Discussions also often arise concerning the role of age, gender and of non-CV co-morbidities for decisions about long-term prevention with drugs. How reliable and applicable are 'evidence-based' guidelines derived from trials in highly selected patients and healthy subjects for the general population seen in everyday practice? Increasingly, the economic aspects of long-term prevention and problems of a fair allocation of limited healthcare resources are also important issues giving rise to contrasting views among patients, doctors, insurance providers and politicians. What are the priorities and who should decide? Ethical considerations relating to the above questions in CV prevention are discussed in this article.
- 10 November 2009
- Published by Wiley in Fundamental & Clinical Pharmacology
- Vol. 23 (6) , 669-673
Ethical considerations in cardiovascular prevention
The fundamental values in medical ethics include the following aspects of professional conduct: (i) actions in the best interest of patients; (ii) first, do no harm; (iii) patients' right to refuse or choose treatments; (iv) fairness and equality in the distribution of healthcare resources; and (v) truthfulness and honesty (informed consent). These values have to be considered in all diagnostic steps and therapeutic decisions. They should also form the basis for discussions of potential conflicts of interest among patients, doctors, healthcare financers and politicians. Cardiovascular (CV) diseases represent the most frequent cause of death and a major healthcare problem in most regions of the world. CV prevention is therefore an important task both in individual subjects and as a means to improve health in the general population. While the merits of treatment in patients with established CV diseases, i.e. secondary prevention, are widely accepted and regarded as necessary, primary prevention with drugs in apparently healthy individuals at an increased risk of future CV events is not free of controversies. The different types of prevention envisaged also give rise to ethical questions: Should all the growing number of classical and newly recognised CV risk markers be a reason for intervention or should they be preferably used for calculating a total risk score? What are the compelling or only relative indications for anti-hypertensive, cholesterol-lowering, anti-diabetic or platelet-inhibiting drugs? Are pre-hypertension, pre-diabetes and marginally elevated cholesterol levels early diseases justifying drug treatment, regardless of the possibility that some prophylactic interventions may be associated with adverse events? Discussions also often arise concerning the role of age, gender and of non-CV co-morbidities for decisions about long-term prevention with drugs. How reliable and applicable are 'evidence-based' guidelines derived from trials in highly selected patients and healthy subjects for the general population seen in everyday practice? Increasingly, the economic aspects of long-term prevention and problems of a fair allocation of limited healthcare resources are also important issues giving rise to contrasting views among patients, doctors, insurance providers and politicians. What are the priorities and who should decide? Ethical considerations relating to the above questions in CV prevention are discussed in this article.
- 1 November 2009
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 102 (11) , 785-789
Challenging the dogma of high target doses in the treatment of heart failure: Is more always better?
- 1 November 2009
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 102 (11) , 785-789
Challenging the dogma of high target doses in the treatment of heart failure: Is more always better?
- Open Access
- 1 March 2009
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 3, 73-78
Newer treatments for decompensated heart failure: focus on levosimendan
Newer treatments for decompensated heart failure: focus on levosimendan Ferenc FollathUniversity Hospital Zürich, Steering Group Drug Therapy, Zürich, Switzerland Acute heart failure (AHF) is a major cause of hospitalizations. Severe dyspnea, pulmonary congestion and low cardiac output with peripheral vasoconstriction and renal hypoperfusion is a main form of clinical presentation. Most patients with acute worsening have a pre-existing decompensated chronic heart failure (ADCHF), but AHF may also occur as a first manifestation of a previously unknown heart disease. Myocardial ischemia, cardiac arrhythmias, non-compliance with medication and infections are frequent precipitating factors. Management of AHF depends on the underlying heart disease and cause of decompensation. In patients with ADCHF vasodilators and iv diuretics are first-line drugs for rapid reduction of dyspnea and congestion. In patients with signs of low cardiac output and oliguria, inotropic agents are also often administered to prevent further deterioration. Beta-adrenergic agents and phosphodiesterase inhibitors correct the hemodynamic disturbance, but may also induce arrhythmias and worsen myocardial ischemia. Inotropic therapy therefore remains controversial. A novel class of drugs, the calcium sensitizers, represent a new therapeutic option. Levosimendan was shown to improve myocardial contractility without increasing oxygen requirements and to produce peripheral and coronary vasodilation. Its therapeutic effects and tolerance have been tested in several trials. The present review focuses on the clinical pharmacology and therapeutic utility of levosimendan in patients with ADCHF.Keywords: acute heart failure, inotropic agents, calcium sensitizers, levosimendan
- 1 March 2009
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 3, 73-78
Open AccessNewer treatments for decompensated heart failure: focus on levosimendan
Newer treatments for decompensated heart failure: focus on levosimendan Ferenc FollathUniversity Hospital Zürich, Steering Group Drug Therapy, Zürich, Switzerland Acute heart failure (AHF) is a major cause of hospitalizations. Severe dyspnea, pulmonary congestion and low cardiac output with peripheral vasoconstriction and renal hypoperfusion is a main form of clinical presentation. Most patients with acute worsening have a pre-existing decompensated chronic heart failure (ADCHF), but AHF may also occur as a first manifestation of a previously unknown heart disease. Myocardial ischemia, cardiac arrhythmias, non-compliance with medication and infections are frequent precipitating factors. Management of AHF depends on the underlying heart disease and cause of decompensation. In patients with ADCHF vasodilators and iv diuretics are first-line drugs for rapid reduction of dyspnea and congestion. In patients with signs of low cardiac output and oliguria, inotropic agents are also often administered to prevent further deterioration. Beta-adrenergic agents and phosphodiesterase inhibitors correct the hemodynamic disturbance, but may also induce arrhythmias and worsen myocardial ischemia. Inotropic therapy therefore remains controversial. A novel class of drugs, the calcium sensitizers, represent a new therapeutic option. Levosimendan was shown to improve myocardial contractility without increasing oxygen requirements and to produce peripheral and coronary vasodilation. Its therapeutic effects and tolerance have been tested in several trials. The present review focuses on the clinical pharmacology and therapeutic utility of levosimendan in patients with ADCHF.Keywords: acute heart failure, inotropic agents, calcium sensitizers, levosimendan
- Open Access
- 1 March 2008
- Published by FapUNIFESP (SciELO) in Arquivos Brasileiros de Cardiologia
- Vol. 90 (3) , 161-162
Podemos acreditar na levosimendana?
- 1 March 2008
- Published by FapUNIFESP (SciELO) in Arquivos Brasileiros de Cardiologia
- Vol. 90 (3) , 161-162
Open AccessPodemos acreditar na levosimendana?
- Open Access
- 1 September 2006
- Published by FapUNIFESP (SciELO) in Arquivos Brasileiros de Cardiologia
- Vol. 87 (3) , 369-377
Tratamento atual da insuficiência cardíaca descompensada
O tratamento de ICD representa um desafio até mesmo para o médico experiente. Os avanços alcançados nas pesquisas propiciaram novas opções de tratamento que estão ajudando a mudar paradigmas. As evidências indicam que novos fármacos como a levosimendana e nesiritida representarão importantes alternativas ou complementos ao tratamento com medicamentos inotrópicos tradicionais, como a dobutamina. O médico responsável pelo tratamento desses pacientes deve aprender a usar as melhores evidências disponíveis para individualizar o tratamento com segurança e eficácia. Treatment of DHF is a challenge even for the experienced physician. Advances in research have brought new treatment options that are helping change paradigms. The available evidence suggests that new drugs like levosimendan and nesiritide will assume relevant positions as alternatives or complements to treatment with traditional inotropic drugs like dobutamine. The physician responsible for treating these patients should learn how to use the best available evidence, in order to tailor treatment with safety and efficacy
- 1 September 2006
- Published by FapUNIFESP (SciELO) in Arquivos Brasileiros de Cardiologia
- Vol. 87 (3) , 369-377
Open AccessTratamento atual da insuficiência cardíaca descompensada
O tratamento de ICD representa um desafio até mesmo para o médico experiente. Os avanços alcançados nas pesquisas propiciaram novas opções de tratamento que estão ajudando a mudar paradigmas. As evidências indicam que novos fármacos como a levosimendana e nesiritida representarão importantes alternativas ou complementos ao tratamento com medicamentos inotrópicos tradicionais, como a dobutamina. O médico responsável pelo tratamento desses pacientes deve aprender a usar as melhores evidências disponíveis para individualizar o tratamento com segurança e eficácia. Treatment of DHF is a challenge even for the experienced physician. Advances in research have brought new treatment options that are helping change paradigms. The available evidence suggests that new drugs like levosimendan and nesiritide will assume relevant positions as alternatives or complements to treatment with traditional inotropic drugs like dobutamine. The physician responsible for treating these patients should learn how to use the best available evidence, in order to tailor treatment with safety and efficacy
- Open Access
- 1 June 2006
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 8 (suppl_C) , C28-C34
Beta-blockade today: the gap between evidence and practice
Current European Society of Cardiology guidelines for chronic heart failure (CHF) recommend the use of beta-blockers in all symptomatic patients with systolic dysfunction. Beta-blockers reduce CHF mortality by >30% and also reduce hospitalizations. Given at appropriate doses, they are generally well tolerated, even in the elderly. However, two large European surveys [IMPROVEMENT in primary care and Euro Heart Failure Survey (EURO-HF) in hospitalized patients] show that beta-blockers are used in only 34–37% of patients, with a wide variation between countries. The frequency of beta-blocker prescription in patients ≥75 years of age is <20%. A recent analysis of EURO-HF showed that, even among CHF patients who met the criteria for the landmark trials, without comorbidities or other risk factors, beta-blockers are used in <50% of cases. General practitioners and internists prescribe beta-blockers less frequently than cardiologists. This difference may be partly due to the fact that patients treated by non-specialists tend to be older and have more comorbidities. Another problem is the fear of side effects with beta-blockers. This is often due to lack of experience (particularly among primary care physicians), as in the past beta-blockers were considered contraindicated in CHF. Frequently cited reasons for not prescribing beta-blockers are advanced age, severe symptoms, and comorbidities (e.g. chronic lung disease, diabetes). In fact, most problems can be avoided if beta-blockers are started at a very low dose and titrated up step by step to the maximum tolerated dose. Mortality benefits are achieved even at doses much lower than the targets used in clinical trials. The CIBIS III results should now help to eliminate most of the doubts regarding the efficacy and tolerability of beta-blockade, even in the elderly patient population.
- 1 June 2006
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 8 (suppl_C) , C28-C34
Open AccessBeta-blockade today: the gap between evidence and practice
Current European Society of Cardiology guidelines for chronic heart failure (CHF) recommend the use of beta-blockers in all symptomatic patients with systolic dysfunction. Beta-blockers reduce CHF mortality by >30% and also reduce hospitalizations. Given at appropriate doses, they are generally well tolerated, even in the elderly. However, two large European surveys [IMPROVEMENT in primary care and Euro Heart Failure Survey (EURO-HF) in hospitalized patients] show that beta-blockers are used in only 34–37% of patients, with a wide variation between countries. The frequency of beta-blocker prescription in patients ≥75 years of age is <20%. A recent analysis of EURO-HF showed that, even among CHF patients who met the criteria for the landmark trials, without comorbidities or other risk factors, beta-blockers are used in <50% of cases. General practitioners and internists prescribe beta-blockers less frequently than cardiologists. This difference may be partly due to the fact that patients treated by non-specialists tend to be older and have more comorbidities. Another problem is the fear of side effects with beta-blockers. This is often due to lack of experience (particularly among primary care physicians), as in the past beta-blockers were considered contraindicated in CHF. Frequently cited reasons for not prescribing beta-blockers are advanced age, severe symptoms, and comorbidities (e.g. chronic lung disease, diabetes). In fact, most problems can be avoided if beta-blockers are started at a very low dose and titrated up step by step to the maximum tolerated dose. Mortality benefits are achieved even at doses much lower than the targets used in clinical trials. The CIBIS III results should now help to eliminate most of the doubts regarding the efficacy and tolerability of beta-blockade, even in the elderly patient population.
- Open Access
- 16 August 2005
- Published by Elsevier in The American Journal of Cardiology
- Vol. 96 (6) , 80-85
European Experience on the Practical Use of Levosimendan in Patients with Acute Heart Failure Syndromes
- 16 August 2005
- Published by Elsevier in The American Journal of Cardiology
- Vol. 96 (6) , 80-85
Open AccessEuropean Experience on the Practical Use of Levosimendan in Patients with Acute Heart Failure Syndromes
- 1 May 2003
- p. 34S-38S
Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
The novel calcium sensitizer levosimendan improves myocardial contractility without causing an increase in intracellular calcium and cyclic adenosine monophosphate concentrations. It also has a vasodilator action due to an opening of the adenosine triphosphate-sensitive potassium channels. In a double-blind clinical trial levosimendan was compared with dobutamine in 203 patients with severe low-output congestive heart failure. A 24-hour infusion of these inotropic drugs was administered to increase the cardiac output by at least 30% together with a decrease in the pulmonary capillary wedge pressure by > or = 25%. The pre-defined hemodynamic improvement was achieved in 28% of patients receiving levosimendan compared to only 15% with dobutamine (p = 0.022). Levosimendan also reduced the 1- and 6-month mortality more than dobutamine (7.8 vs 17%, p = 0.045 and 26 vs 38%, p = 0.029, respectively). Levosimendan produced less myocardial ischemia and cardiac arrhythmias than dobutamine. Calcium sensitizers offer a new therapeutic possibility in patients with decompensated low-output heart failure.
- 1 May 2003
- p. 34S-38S
Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
The novel calcium sensitizer levosimendan improves myocardial contractility without causing an increase in intracellular calcium and cyclic adenosine monophosphate concentrations. It also has a vasodilator action due to an opening of the adenosine triphosphate-sensitive potassium channels. In a double-blind clinical trial levosimendan was compared with dobutamine in 203 patients with severe low-output congestive heart failure. A 24-hour infusion of these inotropic drugs was administered to increase the cardiac output by at least 30% together with a decrease in the pulmonary capillary wedge pressure by > or = 25%. The pre-defined hemodynamic improvement was achieved in 28% of patients receiving levosimendan compared to only 15% with dobutamine (p = 0.022). Levosimendan also reduced the 1- and 6-month mortality more than dobutamine (7.8 vs 17%, p = 0.045 and 26 vs 38%, p = 0.029, respectively). Levosimendan produced less myocardial ischemia and cardiac arrhythmias than dobutamine. Calcium sensitizers offer a new therapeutic possibility in patients with decompensated low-output heart failure.